The cell of origin of ovarian epithelial tumours

The Lancet Oncology

Volumn 9, Issue 12, 2008, Pages 1191-1197

  Dubeau, Louis ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL TYPE; DISEASE MODEL; EMBRYOLOGY; ENDOMETRIOSIS; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; METAPLASIA; MOLECULAR BIOLOGY; MORPHOLOGY; MUELLERIAN DUCT; NONHUMAN; OVARY CARCINOMA; OVARY FOLLICLE; PRIORITY JOURNAL; UTERINE TUBE CARCINOMA;

EID: 56749103412     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70308-5     Document Type: Note

References (47)

1. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?. Gynecol Oncol 72 (1999) 437-442
2. Altaras M.M., Aviram R., Cohen I., Cordoba M., Weiss E., and Beyth Y. Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. Gynecol Oncol 40 (1991) 230-236
3. August C.Z., Murad T.M., and Newton M. Multiple focal extraovarian serous carcinoma. Int J Gynecol Pathol 4 (1985) 11-23
4. Dalrymple J.C., Bannatyne P., Russell P., et al. Extraovarian peritoneal serous papillary carcinoma. Cancer 64 (1989) 110-115
5. Fromm G.-L., Gershenson D.M., and Silva E.G. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 75 (1990) 89-95
6. Finch A., Beiner M., Lubinski J., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296 (2006) 185-192
7. Levine D.A., Argenta P.A., Yee C.J., et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21 (2003) 4222-4227
8. Olivier R.I., van Beurden M., Lubsen M.A., et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90 (2004) 1492-1497
9. Gillman J. The development of the gonads in man with a consideration of the role of fetal endocrines and the histogenesis of ovarian tumors. Contrib Embryol Carneg Inst 32 (1948) 81-131
10. Gruenwald P. The development of sex cords in the gonads of man and mammals. Am J Anat 70 (1942) 359-397
11. Allen B.M. The embryonic development of the ovary and testes of the mammals. Am J Anat 3 (1904) 89-153
12. Witschi E. Migration of the germ cells of human embryo from the yolk sac to the primitive gonadal folds. Contr Embryol Carnegie Inst 32 (1948) 69-80
13. Rodriguez M., and Dubeau L. Ovarian tumor development: insights from ovarian embryogenesis. Eur J Gynaecol Oncol 22 (2001) 175-183
14. Josso N., di Clemente N., and Gouedart L. Anti-mullerian hormone and its receptors. Mol Cell Endocrinol 179 (2001) 25-32
15. Byskov A.G. Primordial germ cells and regulation of meiosis. In: Austin C.R., and Short R.V. (Eds). Reproduction in mammals. I. Germ cells and fertilization (1982), Cambridge University Press, London 1-16
16. Behringer R.R., Finegold M.J., and Cate R.L. Mullerian-inhibiting substance function during mammalian sexual development. Cell 79 (1994) 415-425
17. Cheng W., Liu J., Yoshida H., Rosen D., and Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 11 (2005) 531-537
18. Colgan T.J., Murphy J., Cole D.E., Narod S., and Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25 (2001) 1283-1289
19. Leeper K., Garcia R., Swisher E., Goff B., Greer B., and Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 87 (2002) 52-56
20. Piek J.M., van Diest P.J., Zweemer R.P., et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195 (2001) 451-456
21. Tonin P., Weber B., Offit K., et al. Frequency of recurrent BRCA1 and BRCA2 mutations in 222 Ashkenazi Jewish breast cancer families. Nat Med 2 (1996) 1179-1183
22. Crum C.P., Drapkin R., Miron A., et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19 (2007) 3-9
23. Scully R.E. Pathology of ovarian cancer precursors. J Cell Biochem Suppl 23 (1995) 208-218
24. Lauchlan S.C. The secondary mullerian system revisited. Int J Gynecol Pathol 13 (1994) 73-79
25. Rutgers J.L., and Scully R.E. Cysts (cystadenomas) and tumors of the rete ovarii. Int J Gynecol Pathol 7 (1988) 330-342
26. Byskov A.G. Does the rete ovarii act as a trigger for the onset of meiosis?. Nature 252 (1974) 396-397
27. Quattropani S.L. Serous cystadenoma formation in guinea pig ovaries. J Submicrosc Cytol 13 (1981) 337-345
28. Brinton L.A., Gridley G., Persson I., Baron J., and Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176 (1997) 572-579
29. Heaps J.M., Nieberg R.K., and Berek J.S. Malignant neoplasms arising in endometriosis. Obstet Gynecol 75 (1990) 1023-1028
30. Ness R.B. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 189 (2003) 280-294
31. Ness R.B., and Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91 (1999) 1459-1467
32. Prefumo F., Todeschini F., Fulcheri E., and Venturini P.L. Epithelial abnormalities in cystic ovarian endometriosis. Gynecol Oncol 84 (2002) 280-284
33. Vignali M., Infantino M., Matrone R., et al. Endometriosis: novel etiopathogenetic concepts and clinical perspectives. Fertil Steril 78 (2002) 665-678
34. Kadar N., and Krumerman M. Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor). Gynecol Oncol 59 (1995) 394-397
35. Zheng J.P., Robinson W.R., Ehlen T., Yu M.C., and Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. Cancer Res 51 (1991) 4045-4051
36. Quddus M.R., Sung C.J., and Lauchlan S.C. Benign and malignant serous and endometrioid epithelium in the omentum. Gynecol Oncol 75 (1999) 227-232
37. Cornelison T.L., Natarajan N., Piver M.S., and Mettlin C.J. Tubal ligation and the risk of ovarian carcinoma. Cancer Detect Prev 21 (1997) 1-6
38. Cramer D.W., and Xu H. Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann Epidemiol 5 (1995) 310-314
39. Green A.C., Purdie D.M., Bain C.J., et al. Tubal sterilization, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Group. Int J Cancer 71 (1997) 948-951
40. Hankinson S.E., Hunter D.J., Colditz G.A., et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270 (1993) 2813-2818
41. Irwin K.L., Weiss N.S., Lee N.C., and Peterson H.B. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol 134 (1991) 362-369
42. Kreiger N., Sloan M., Cotterchio M., and Parsons P. Surgical procedures associated with risk of ovarian cancer. Int J Epidemiol 26 (1997) 710-715
43. Loft A., Lidegaard O., and Tabor A. Incidence of ovarian cancer after hysterectomy: a nationwide controlled follow up. Br J Obstet Gynaecol 104 (1997) 1296-1301
44. Miracle-McMahill H.L., Calle E.E., Kosinski A.S., et al. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol 145 (1997) 349-447
45. Rosenblatt K.A., and Thomas D.B. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. Cancer Epidemiol Biomarkers Prev 5 (1996) 933-935
46. Weiss N.S., and Harlow B.L. Why does hysterectomy without bilateral oophorectomy influence the subsequent incidence of ovarian cancer?. Am J Epidemiol 124 (1986) 856-858
47. Chodankar R., Kwang S., Sangiorgi F., et al. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 15 (2005) 561-565